All In Biotech

Drug Trial Radar · NCT06716424

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

Multicentre Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

105

Actual

Start

Jan 6, 2025

Primary completion

Jun 12, 2026

Study completion Jun 12, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.

Conditions

  • Type 2 Diabetes

Interventions

  • iGlarLixi (insulin glargine/lixisenatide)Drug

    iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs)Time frame: From Day 1 to Week 25

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 3560009

    Bengaluru, India

  • Investigational Site Number : 3560007

    Delhi, India

  • Investigational Site Number : 3560005

    Hyderabad, India

  • Investigational Site Number : 3560006

    Indore, India

  • Investigational Site Number : 3560011

    Jaipur, India

  • Investigational Site Number : 3560003

    Kanpur, India

  • Investigational Site Number : 3560001

    Kolkata, India

  • Investigational Site Number : 3560008

    Pune, India

  • Investigational Site Number: 3560013

    Pune, India

  • Investigational Site Number : 3560014

    Visakhapatnam, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.